OPF-310 encapsulated porcine islets
Otsuka Pharmaceutical Factory
What it is
First-in-human xenotransplant program using encapsulated neonatal pig islet cells for adults with unstable T1D and repeated severe hypoglycemia despite closed-loop therapy. It is a bold supply-and-protection strategy, but still phase 1/2 with no peer-reviewed human efficacy results.
Editorial review: .
Most recent recorded citation date: 2026-02-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Insulin independence: The trial measures efficacy, but no peer-reviewed insulin-independence or C-peptide outcomes are posted yet.[1]
- Important harms and treatment burden
- Immunosuppression-free: The central promise is protective encapsulation of porcine islets, aiming to avoid systemic immunosuppression; clinical proof is still pending.[2]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Porcine islets could solve supply, but long-term survival, fibrosis resistance and glucose-responsive function in humans are unanswered.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 70 × 30 + 15 × 20 + 15 × 20 + 25 × 10 + 20 × 5 + 25 × 15 = 3425; divide by total weight 100. Unrounded weighted result: 34.25.
The central promise is protective encapsulation of porcine islets, aiming to avoid systemic immunosuppression; clinical proof is still pending.[2]
The trial measures efficacy, but no peer-reviewed insulin-independence or C-peptide outcomes are posted yet.[1]
Porcine islets could solve supply, but long-term survival, fibrosis resistance and glucose-responsive function in humans are unanswered.[1]
This is a transplanted combination product, not a simple infusion or drug; the exact implant burden matters and remains specialist-care only.[1]
First study is limited to ages 35-70 with unstable T1D and repeated severe hypoglycemia despite closed-loop therapy.[1]
The full picture
OPF-310 is unusual because it attacks two bottlenecks at once: cell supply and immune protection. Human donor islets are scarce; pig islets are potentially scalable. But xenotransplantation only becomes broadly useful if the encapsulation device protects cells from immune attack and fibrosis while still letting oxygen, glucose and insulin move fast enough. The current trial starts with a narrow first population: unstable, high-risk T1D with severe hypoglycemia despite closed-loop therapy. It is not yet a proven cure.
Coming soon
ETA · Phase 1/2 recruiting; primary completion estimated 2027
Sources
- [1]
- [2]Spotlight on OPF-310: a porcine-derived cell therapy in clinical trials · Science journalism · 2026-02-01
- [3]New T1D Practical Cure Trial Uses Pig Islets · Science journalism · 2025-08-07